Literature DB >> 22372927

A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.

Mirko Zimic1, Sebastian Loli, Robert H Gilman, Andrés Gutierrez, Patricia Fuentes, Milagros Cotrina, Daniela Kirwan, Patricia Sheen.   

Abstract

BACKGROUND: Pyrazinamide (PZA) is an important drug in the treatment of tuberculosis. Microbiological methods of PZA susceptibility testing are controversial and have low reproducibility. After conversion of PZA into pyrazinoic acid (POA) by the bacterial pyrazinamidase enzyme, the drug is expelled from the bacteria by an efflux pump.
OBJECTIVE: To evaluate the rate of POA extrusion from Mycobacterium tuberculosis as a parameter to detect PZA resistance.
METHODS: The rate of POA extrusion and PZA susceptibility determined by BACTEC 460 were measured for 34 strains in a previous study. PZA resistance was modeled in a logistic regression with the pyrazinoic efflux rate. RESULT: POA efflux rate predicted PZA resistance with 70.83%-92.85% sensitivity and 100% specificity compared with BACTEC 460.
CONCLUSION: POA efflux rate could be a useful tool for predicting PZA resistance in M. tuberculosis. Further exploration of this approach may lead to the development of new tools for diagnosing PZA resistance, which may be of public health importance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22372927      PMCID: PMC3462410          DOI: 10.1089/mdr.2011.0207

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  20 in total

1.  Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Fuentes; Robert H Gilman; Andrés H Gutiérrez; Daniela Kirwan; Patricia Sheen
Journal:  Tuberculosis (Edinb)       Date:  2011-10-17       Impact factor: 3.131

2.  pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.

Authors:  S J Cheng; L Thibert; T Sanchez; L Heifets; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations.

Authors:  L Heifets; P Lindholm-Levy
Journal:  Am Rev Respir Dis       Date:  1992-05

4.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli.

Authors:  K Konno; F M Feldmann; W McDermott
Journal:  Am Rev Respir Dis       Date:  1967-03

5.  The action of antituberculosis drugs in short-course chemotherapy.

Authors:  D A Mitchison
Journal:  Tubercle       Date:  1985-09

Review 6.  The curious characteristics of pyrazinamide: a review.

Authors:  Y Zhang; D Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2003-01       Impact factor: 2.373

Review 7.  The role of pyrazinamide in tuberculosis chemotherapy.

Authors:  M A Steele; R M Des Prez
Journal:  Chest       Date:  1988-10       Impact factor: 9.410

8.  Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.

Authors:  Ying Zhang; Mary Margaret Wade; Angelo Scorpio; Hao Zhang; Zhonghe Sun
Journal:  J Antimicrob Chemother       Date:  2003-10-16       Impact factor: 5.790

9.  Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001.

Authors:  L Vásquez-Campos; L Asencios-Solis; E Leo-Hurtado; N Quispe-Torres; E Salazar-Lindo; J Bayona; M C Becerra
Journal:  Int J Tuberc Lung Dis       Date:  2004-04       Impact factor: 2.373

Review 10.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.

Authors:  Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye
Journal:  Arch Intern Med       Date:  2003-05-12
View more
  6 in total

1.  pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Patricia Sheen; Katherine Lozano; Robert H Gilman; Hugo J Valencia; Sebastian Loli; Patricia Fuentes; Louis Grandjean; Mirko Zimic
Journal:  Tuberculosis (Edinb)       Date:  2013-07-16       Impact factor: 3.131

2.  Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh.

Authors:  Arfatur Rahman; Sara Sabrina Ferdous; Shahriar Ahmed; S M Mazidur Rahman; Mohammad Khaja Mafij Uddin; Suporn Pholwat; Jean Gratz; Eric Houpt; Sayera Banu
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis.

Authors:  Juliane Havlicek; Beatrice Dachsel; Peter Slickers; Sönke Andres; Patrick Beckert; Silke Feuerriegel; Stefan Niemann; Matthias Merker; Ines Labugger
Journal:  Diagn Microbiol Infect Dis       Date:  2018-12-30       Impact factor: 2.803

4.  Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.

Authors:  Hui Xia; Susan van den Hof; Frank Cobelens; Yang Zhou; Bing Zhao; Shengfen Wang; Yanlin Zhao
Journal:  BMC Infect Dis       Date:  2020-01-07       Impact factor: 3.090

5.  The pyrazinamide susceptibility breakpoint above which combination therapy fails.

Authors:  Tawanda Gumbo; Emmanuel Chigutsa; Jotam Pasipanodya; Marianne Visser; Paul D van Helden; Frederick A Sirgel; Helen McIlleron
Journal:  J Antimicrob Chemother       Date:  2014-05-12       Impact factor: 5.790

6.  A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance.

Authors:  Patricia Sheen; David Requena; Eduardo Gushiken; Robert H Gilman; Ricardo Antiparra; Bryan Lucero; Pilar Lizárraga; Basilio Cieza; Elisa Roncal; Louis Grandjean; Arnab Pain; Ruth McNerney; Taane G Clark; David Moore; Mirko Zimic
Journal:  BMC Genomics       Date:  2017-10-11       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.